IanWinchesterFlinnMD

Oncology • Nashville, TN

Hematologic Oncology

Physician

Join to view full profile

Dr. Flinn is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Flinn's full profile

Already have an account?

Office
250 25th Ave N
Ste 412
Nashville, TN 37203
Phone+1 615-986-7600

Fax+1 615-986-7601

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1993 - 1996
University of MichiganResidency, Internal Medicine, 1990 - 1993
Johns Hopkins University School of MedicineClass of 1990

Certifications & Licensure

TN State Medical License 2006 - 2025
AL State Medical License 2020 - 2020
MD State Medical License 1993 - 2006
MI State Medical License 1992 - 1996
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2008-2014
Nashville Lifestyles Magazine Castle Connolly, 2008, 2011, 2013-2014
America's Top Doctors for Cancer Castle Connolly, 2007-2013

Clinical Trials

Fludarabine With or Without Cyclophosphamide in Treating Patients With Chronic Lymphocytic Leukemia Start of enrollment: 2000 Mar 09
Completed
Phase 3
Alemtuzumab Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Lymphocytic Leukemia Start of enrollment: 2001 Jul 05
Completed
Phase 2
Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed or Progressive B-Cell Diffuse Large Cell Lymphoma Start of enrollment: 2003 Mar 01
Completed
Phase 3
Xcellerated T CellsTM for Non-Hodgkin's Lymphoma (NHL) Patients Start of enrollment: 2004 Mar 01
Unknown status
Phase 2
Rituximab and GM-CSF in Treating Patients With Chronic Lymphocytic Leukemia Start of enrollment: 2005 Jul 01
Terminated
Phase 2
Safety and Efficacy Study of an Anti-CD20 Monoclonal Antibody (AME-133v) to Treat Non-Hodgkin's Lymphoma Start of enrollment: 2006 Jul 01
Completed
Phase 1
Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lymphocytic Leukemia (CLL) Start of enrollment: 2008 Jan 01
Completed
Phase 1, Phase 2
Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma Start of enrollment: 2008 Jun 01
Completed
Phase 1, Phase 2
Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma Start of enrollment: 2010 Mar 01
Completed
Phase 2
Ofatumumab for Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2010 Jul 01
Completed
Phase 2
Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic Leukemia Start of enrollment: 2010 Sep 01
Completed
Phase 1
IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia Start of enrollment: 2012 Jan 01
Completed
Phase 1
A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies Start of enrollment: 2012 Oct 01
Completed
Phase 1
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Start of enrollment: 2013 Jan 16
Terminated
Phase 3
ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas Start of enrollment: 2013 Jan 31
Completed
Phase 3
Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies Start of enrollment: 2013 Mar 14
Terminated
Phase 2
Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma Start of enrollment: 2013 Dec 05
Completed
Phase 1
Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies Start of enrollment: 2013 May 01
Completed
Phase 1
A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma Start of enrollment: 2013 Sep 05
Completed
Phase 1
Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2014 Feb 05
Terminated
Phase 3
Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL Start of enrollment: 2013 Aug 30
Completed
Phase 1, Phase 2
Study of the Glutaminase Inhibitor CB-839 in Leukemia Start of enrollment: 2014 Mar 01
Completed
Phase 1
Selinexor (KPT-330) in Older Patients With Relapsed AML Start of enrollment: 2014 Mar 01
Completed
Phase 2
Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AML Start of enrollment: 2014 Oct 01
Withdrawn
Phase 1
AZD2014 Plus Novel Anti-Cancer Agents in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Start of enrollment: 2016 Jun 01
Withdrawn
Phase 1
Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study) Start of enrollment: 2018 Jun 19
Completed
Phase 1
Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma Start of enrollment: 2018 Nov 28
Active, not recruiting
Phase 2
Roles: Principal Investigator, Contact
Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma Start of enrollment: 2021 Nov 12
Recruiting
Phase 2
Roles: Contact
Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma Start of enrollment: 2023 Jan 02
Recruiting
Phase 1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQ...
Mazyar Shadman, Talha Munir, Tadeusz Robak, Jennifer R Brown, Brad S Kahl
Journal of Clinical Oncology. 2024-12-08
Correction: Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambuci...
Jeff P Sharman, Miklos Egyed, Wojciech Jurczak, Alan Skarbnik, John M Pagel
Leukemia. 2024-12-03
Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Advanced-Stage Classical Hodgkin Lymphoma.
Hun Ju Lee, Rod Ramchandren, Judah Friedman, Jason M Melear, Ian W Flinn
Blood. 2024-12-02

Journal Articles

CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma
Mark P Chao, Sonali M Smith, Ranjana Advani, Ian Flinn, Ravindra Majeti, Nancy L Bartlett, Leslie Popplewell, Justin Kline, Nilanjan Ghosh, Ann LaCasce, The New England Journal of Medicine
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma
Ian W Flinn, Nancy L Bartlett, The New England Journal of Medicine
PI3K Inhibitors and the Search for the Holy Grail
Ian Flinn, MD, Blood
The Phase 3 DUO Trial: Duvelisib Versus Ofatumumab in Relapsed and Refractory CLL/SLL
Matthew S Davids, Ian W Flinn, Craig A Portell, Nicole Lamanna, Scott Lunin, Amanda F Cashen, Blood
Join now to see all

Abstracts/Posters

Analysis of an Online Treatment Decision Tool Reveals Variances in Practice between Experts and Oncology Healthcare Providers for Newly Diagnosed Follicular Lymphoma
Ian W. Flinn, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Final Results of Phase 1, Dose Escalation Study Evaluating ARQ 531 in Patients with Relapsed or Refractory B-Cell Lymphoid Malignancies
Ian W. Flinn, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Results from a First-in-Human, Proof-of-Concept Phase 1 Trial in Pretreated B-Cell Malignancies for Loxo-305, a Next-Generation, Highly Selective, Non-Covalent BTK Inh...
Ian W. Flinn, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
PRISM: A Platform Protocol for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma
Ian W. Flinn, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Debulking Eliminates Need for Hospitalization Prior to Initiating Frontline Venetoclax Therapy in Previously Untreated CLL Patients: A Phase 3b Study
Ian W. Flinn, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Validation of the PRIMA-Prognostic Index for Patients Treated with Rituximab Plus Chemotherapy and Refinement of Prognostic Parameters for Patients on Rituximab Plus L...
Ian W. Flinn, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Brentuximab Vedotin in Combination with Nivolumab, Doxorubucin, and Dacarbazine in Newly Diagnosed Patients with Advanced Stage Hodgkin Lymphoma
Ian W. Flinn, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
CD19-Loss with Preservation of Other B Cell Lineage Features in Patients with Large B Cell Lymphoma Who Relapsed Post_Axi-Cel
Ian W. Flinn, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Results of the Phase...
Ian W. Flinn, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of t...
Ian W. Flinn, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Exposure-Response Analyses Indicate a Promising Benefit/Risk Profile of Mosunetuzumab in Relapsed and Refractory Non-Hodgkin Lymphoma
Ian W. Flinn, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Long-Term Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Nilotinib Versus Imatinib: Enestnd 10-Year Analysis
Ian W. Flinn, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

ZUMA-8: A phase 1/2 multicenter study evaluating KTE-X19 in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).
ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019
Effect of dose modifications on response to duvelisib in patients with relapsed/refractory (R/R) CLL/SLL in the DUO trial.
ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019
Advancing the Role of BTK Inhibitors in B-Cell Malignancies: Expert Guidance for Clinical Management
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Efficacy and Safety of Venetoclax (Ven) + Rituximab (R) or Ven + Bendamustine (B) + R Randomized Versus B + R in Patients (pts) with Relapsed/Refractory (R/R) Follicul...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Avadomide (CC-), a Novel Cereblon Modulating Agent, Plus Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Clinical and Biological Indicators of Duvelisib Efficacy in CLL from the Phase 3 DUOTM Study
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Clinical and Biological Indicators of Duvelisib Efficacy in CLL from the Phase 3 DUOTM Study
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
PI3 Kinase Inhibitors: Community Perspectives for Optimizing Therapy
60th American Society of Hematology Annual Meeting - 11/30/2018
Join now to see all

Press Mentions

SGN35-027: Brentuximab Vedotin with Nivolumab, Doxorubicin, and Dacarbazine in HLFebruary 24th, 2022
Tisagenlecleucel Promising in R/R Follicular LymphomaJanuary 11th, 2022
Will Bispecific Antibodies Challenge CAR T-cell Therapy in Follicular Lymphoma?December 21st, 2021
Join now to see all